Move to topTop

Leuven, Belgium - March 27, 2015

Based on the current information it disposes of, the Belgian Federal Agency for Medicines and Health Products (FAMHP) advises not to suspend nor stop any treatments involving Terumo injection needles.

On March 25, the Terumo production site of Leuven received an inspection of the Belgian Federal Agency for Medicines and Health Products (FAMHP). After a first analysis of the issue and based on the information they currently dispose of, the FAMHP advises patients not to suspend nor stop any treatments with Terumo injection needles.

"We have cooperated with FAMHP in full transparency during the inspection at our Leuven production site. We will continue to closely work with the authorities in the following weeks, as patient safety and the highest quality standards always come first at Terumo," concludes Kyo Nishikawa, Managing Director Terumo Europe.

    About Terumo

    Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

    Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

     

    Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.